https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-14 08:43:072026-04-14 08:43:07Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-14 08:43:072026-04-14 08:43:07Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development
https://www.optimumcomms.com/wp-content/uploads/2026/02/Laigo-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-14 08:33:572026-04-14 08:34:19Laigo Bio strengthens team with Chief Scientific Officer and Scientific Advisory Board appointments
https://www.optimumcomms.com/wp-content/uploads/2026/03/Mestag_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-14 08:33:552026-04-14 08:33:55Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2026/01/Kainova_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-09 08:46:572026-04-09 08:46:57Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-08 17:22:332026-04-08 17:22:56Hansa Biopharma to host Q1 2026 interim results conference call
https://www.optimumcomms.com/wp-content/uploads/2026/04/SonoNeu_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-04-07 08:07:032026-04-07 08:07:03SonoNeu exits stealth as key part of US Government-funded research program worth up to $41.3m to advance sonogenetics into clinic
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-31 08:33:582026-03-31 08:33:58Grant of first POLB 001 cancer immunotherapy-induced CRS patent
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-26 08:34:052026-03-26 08:34:05Hansa Biopharma publishes 2025 Annual and Sustainability Reports
https://www.optimumcomms.com/wp-content/uploads/2026/02/Laigo-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-23 08:50:032026-03-23 08:50:03Laigo Bio completes final close of oversubscribed seed financing of €17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
https://www.optimumcomms.com/wp-content/uploads/2025/07/hansa.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-20 09:13:472026-03-20 09:13:47Hansa Biopharma announces a USD 30 million convertible note financing
https://www.optimumcomms.com/wp-content/uploads/2026/02/BOOSTPharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-19 11:30:522026-04-01 12:29:59BOOST Pharma Appoints Leading Biopharma Leader Elaine Jones as Chair
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-19 08:38:462026-03-19 08:38:46Oncoinvent secures new patent expanding protection for Radspherin®
https://www.optimumcomms.com/wp-content/uploads/2026/01/Atrogi_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-18 08:34:592026-03-18 08:34:59Atrogi announces first subjects dosed in human trial for lead candidate ATR-258
https://www.optimumcomms.com/wp-content/uploads/2026/03/AMS_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-18 07:10:522026-03-18 07:10:52Advanced Medical Solutions Group plc: Unaudited preliminary results for the year ended 31 December 2025
https://www.optimumcomms.com/wp-content/uploads/2026/03/R1_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-17 12:28:512026-03-17 12:28:51R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease
https://www.optimumcomms.com/wp-content/uploads/2024/04/Outrun_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-03-17 08:35:202026-03-17 08:35:20Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
